Following updated Government and Health Authority advice, to reduce the spread of COVID 19 and to reduce any risks to our employees, all employees across the Group are working from home, aside from those critical to the continued manufacture of our products. As part of our commitment to putting patients first, we are continually monitoring our supply chain and manufacturing capabilities and are confident that we will continue to be able to supply our allergy therapies and diagnostics. We continue to monitor the situation and are committed to maintain our mission of transforming allergy treatment.